Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report

Owing to their survival benefits, immune checkpoint inhibitors (ICIs) have emerged as the mainstay treatment for several types of malignant tumors including renal cell carcinoma (RCC). However, the usage of ICIs such as nivolumab, ipilimumab, and atezolizumab can be complicated by unexpected rapid c...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkader, Mohammad, Altaha, Rashed, Alkhatib, Lean, Jabali, Eslam H, Alsoreeky, Mohammad S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651922/
https://www.ncbi.nlm.nih.gov/pubmed/36381823
http://dx.doi.org/10.7759/cureus.30194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651922/
https://www.ncbi.nlm.nih.gov/pubmed/36381823
http://dx.doi.org/10.7759/cureus.30194

Ejemplares similares